Quartet adds $6.25 mln in Series A funding

Quartet Medicine said Wednesday it raised another $6.25 million, boosting its Series A to a total of $23.25 million. New investors include Remeditex Ventures LLC and two undisclosed Shanghai-based strategic investors. Quartet, of Cambridge, Massachusetts, is a biotechnology company focused on the development of novel treatments for chronic pain and inflammation.

North AmericaUSBriefs